New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2013
07:38 EDTARWRArrowHead begins phase 1 trial of ARC-520 for Hepatitis B infection treatment
Arrowhead Research announced that it has initiated dosing in a Phase 1 clinical trial of ARC-520, the company’s candidate for the treatment of chronic hepatitis B virus infection. Trial initiation followed successful completion of the Clinical Trial Notification regulatory process in Australia. The objectives of the study are to characterize the safety profile of ARC-520, determine maximum tolerated dose, and evaluate pharmacokinetics in healthy volunteers.The Phase 1 trial is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers and is being conducted in Melbourne, Australia. Each dose cohort includes 6 subjects randomized at ratio of 1:2 to receive a single intravenous injection of either placebo or ARC-520. Arrowhead expects to complete this Phase 1 trial in Q4 and begin a Phase 2a trial in chronic HBV patients in 2014.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:31 EDTARWRArrowhead management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
07:44 EDTARWRArrowhead management to meet with Deutsche Bank
Meetings to be held in Minneapolis/Chicago on October 23 hosted by Deutsche Bank.
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
October 13, 2014
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use